Introduction {#s1}
============

Today, cardiovascular disease (CVD) is one of the leading causes of mortality, disability, and morbidity in adults worldwide.^[@EHS458C1]^ To identify persons at an increased risk of CVD, several score systems have previously been developed.^[@EHS458C2]^ The European Society of Cardiology (ESC) has created a systematic coronary risk evaluation (SCORE system) chart based on five well-established risk factors: age, sex, total serum cholesterol (s-cholesterol), systolic blood pressure (SBP), and smoking.^[@EHS458C3]^ In contrast to the Framingham risk score,^[@EHS458C4],[@EHS458C5]^ which was based on a single North-American community, the ESC model is derived from 12 large European cohort studies. This would make the ESC model more reliable and applicable to European conditions. However, the European score model uses only fatal CVD events which may limit the predictive power substantially. In addition, various risk models predict only the 10-year risk for a population aged up to 65 years, whereas the majority of CVD events occur in elderly people which may lead to underestimation of the real importance of these risk factors.^[@EHS458C6]^ Finally many risk models focus on both coronary heart disease (CHD) and stroke simultaneously, and these two outcomes may differ considerably in predictability.

To address these issues, we investigated the differences between the short-term and long-term (10 year and 35 year) cumulative risk of developing either a first time CHD or stroke, based on the risk factors used by the ESC SCORE model in 7174 middle-aged men from Gothenburg in Sweden who were followed for 35 years. Additionally, we estimated the long-term impact of individual risk factors for both CHD and stroke separately.

Methods {#s2}
=======

Study population {#s2a}
----------------

The Multifactor Primary Prevention Study was first established in 1970 and was designed as an intervention trial. It included all men in Gothenburg born between 1915 and 1925 (with the exception of 1923). A third of the men were randomly selected for the intervention group which comprised 10 000 men, with interventions directed against smoking, hypertension, and hypercholesterolaemia.^[@EHS458C7]^ Additionally, two control groups with 10 000 men each were established. For the intervention group that forms the basis for this investigation, a postal questionnaire with an invitation letter was sent to all the men. Those who responded (*n*= 7495) were invited for a first baseline screening in 1970--73. After 4 and 10 years, re-examinations were performed in a random sample (20%) of both the intervention and control groups. No significant differences were found in risk factor levels \[e.g. s-cholesterol, blood pressure (BP), and smoking status\], cardiovascular, cancer, or all-cause mortality between the intervention and control groups. Consequently, any changes observed in the intervention group occurred to the same extent as in the general population. Thus, the present study group is considered to be representative of the background population in the city. Further details of study design and criteria for entering the study have previously been described.^[@EHS458C7]^

The present study uses baseline information from those individuals in the intervention group with no previous history of CHD, stroke, or diabetes and with a complete data set, leaving a total of 7174 men aged 47--55 years (mean age 51). In addition, all participants gave their informed consent to participate in the study. The study complies with the Declaration of Helsinki and was approved by the Ethics Committee for Medical Research at University of Gothenburg.

Definition of risk factors {#s2b}
--------------------------

In the current study, CVD is defined as CHD (myocardial infarction) and stroke. To estimate the risk of developing a CVD event, the following major risk factors were used: SBP, diastolic blood pressure (DBP), s-cholesterol, hypertension, antihypertensive treatment, and smoking status at baseline. All screening examinations were performed during the afternoon, including weight, height, and BP (taken after 5 min rest with the subject seated). Hypertension was defined as SBP \>140 or DBP \>90 or receiving antihypertensive treatment. For the determination of s-cholesterol, samples were taken after ≥2 h fasting and s-cholesterol concentration was determined according to standard laboratory procedures. Information on smoking habits and previous history of CHD or stroke was collected from the postal questionnaire. Non-smokers were defined as either never or ex-smoker (\>3 months) and the rest as current smokers.

Definition of risk groups {#s2c}
-------------------------

The following five risk groups were created based on the ESC SCORE chart for men aged 50 using the risk factors SBP, s-cholesterol, and smoking status.^[@EHS458C3]^ All participants were stratified into one of five risk groups based on their number of risk factors at baseline (1970--73). According to the ESC SCORE chart, optimal levels for SBP and s-cholesterol are set to 120 mmHg and 4 mmol/L. However, at the time of baseline investigation, the mean BP (SBP and DBP) were high in comparison with levels of today. To create a sufficiently large group, optimal levels for SBP and s-cholesterol was defined at higher cut-off points than would currently have been the case. Optimal risk: SBP \<140 mmHg without antihypertensive treatment, s-cholesterol \<5.0 mmol/L and non-smoker.Low risk: SBP 140--159 mmHg without antihypertensive treatment and/or s-cholesterol 5.0--5.9 mmol/L and non-smoker.Moderate risk: SBP ≥160 mmHg or antihypertensive treatment or s-cholesterol ≥6.0 mmol/L or current smoker.Elevated risk: SBP ≥160 mmHg or antihypertensive treatment and/or s-cholesterol ≥6.0 mmol/L and/or current smoker.High risk: SBP ≥160 mmHg or antihypertensive treatment, s-cholesterol ≥6.0 mmol/L and current smoker.Men with low risk were selected as the reference group.

Follow-up procedure {#s2d}
-------------------

The follow-up was extended through 2008 with endpoints of first time CHD and stroke events registered from several sources. For individuals up to 65 years of age, both CHD and stroke events were recorded using criteria from the local CHD and stroke registers.^[@EHS458C8],[@EHS458C9]^ Case records for all hospital diagnoses were checked manually by one nurse and one medical technician from the start of the study. Furthermore, all hospital discharges from Gothenburg have been reported to the national register since 1970 (except for 1976 due to legislative changes). A file of all participants of the study was run against the national register of hospital discharges 1970--2008. In addition, all men in the study were matched against the Swedish Cause of Death register.

The International Classification of Disease (ICD) was used to identify CHD and stroke events and for this purpose ICD version 8 was used until 1986, ICD-9 from 1987 to 1996 and the last revision ICD-10 was used from 1997. In this present study, both non-fatal and fatal events were considered. For CHD, the following discharge codes were used: ICD-8 and ICD-9 code 410 and ICD-10 code I21. For stroke: ICD-9 codes 431, 433, 434, and 436 and ICD-10 codes I61-I64 were used.

Statistical analysis {#s2e}
--------------------

Statistical analyses were performed with the SAS (ver. 9.2) and R statistical system (ver. 2.15.1). Descriptive statistics with baseline characteristics are presented for each risk factor and risk groups. The individual risk factors were categorized into different levels where the age-adjusted incidence rate ratios (IRRs) were calculated for stroke and CHD, respectively.

In long-term follow-up studies, it is important to apply a statistical model which accounts for competing events (e.g. death as a competing risk) that could potentially end the follow-up for a study subject in such a way that violates the random censoring assumption when calculating risk differences in risk factors. To calculate the risk of stroke and CHD, a modified Cox regression analysis as described by Fine JP and Gray RJ was used in a competing risk setting.^[@EHS458C10]^ From the competing risk regression analysis the subdistribution hazard ratio (SHR) with two-sided 95% confidence intervals (CI) was estimated for individual risk factors and risk groups. All estimates were adjusted for age where each categorized risk level (based on the different levels of the categorized risk factors) was compared with the corresponding reference group. In addition, both the short-term (0--10 year) and long-term (0--35 year) cumulative incidence (cuminc) curves were estimated. The R package 'cmprsk' which is publicity available at the R archive network site (<http://cran.r-project.org/> was used to calculate the SHR and cuminc).^[@EHS458C10]--[@EHS458C12]^

Results {#s3}
=======

Long-term effect of individual risk factors {#s3a}
-------------------------------------------

Among the 7174 men in the study, 2417 (33.7%) experienced a first CHD event and 1335 (18.6%) a first stroke over the 35-year follow-up. In total, 3752 (52.3%) of the men experienced a CVD event over the 35-year follow-up. The distribution of risk factors and groups at baseline is outlined in *Table [1](#EHS458TB1){ref-type="table"}*. Table 1Baseline characteristics of the study populationMean (SD)^a^Number of men, *n* = 7174 (% of total)Age (years)51.5±2.3S-cholesterol levels \<5.0 mmol/L6.5±1.1703 (9.8) 5.0--5.9 mmol/L1986 (27.7) 6.0--6.9 mmol/L2364 (32.9) ≥7.0 mmol/L2121 (29.6)SBP \<140 mmHg148.5±21.82552 (35.6) 140--159 mmHg2573 (35.9) ≥160 mmHg2049 (28.6)Smoking habits Non-smoker3577 (49.9) Smoker3597 (50.1)Hypertension Non-hypertensive2171 (30.3) Hypertensive5003 (69.7) Antihypertensive medication367 (5.1)Risk groups^b^ Optimal risk130 (1.8) Low risk842 (11.7) Moderate risk2867 (40.0) Elevated risk2645 (36.9) High risk690 (9.6)[^1][^2]

*Table [2](#EHS458TB2){ref-type="table"}* shows the age-adjusted SHR for individual risk factors (SBP, s-cholesterol, hypertension, antihypertensive medication, and smoking status) after 35 years of follow-up. High s-cholesterol (SHR: 1.93, 95% CI: 1.65--2.26) and SBP (SHR: 1.68, 95% CI: 1.52--1.86) at baseline were the two most significant risk factors for CHD, followed by antihypertensive medication (SHR: 1.55, 95% CI: 1.31--1.82), hypertension (SHR:1.51, 95% CI: 1.38--1.66) and current smoking at baseline (SHR: 1.26, 95% CI: 1.16--1.36). For stroke, a significant risk increase was found for high SBP (SHR: 1.37, 95% CI: 1.20--1.57), antihypertensive medication (SHR: 1.31, with 95% CI: 1.05--1.64), and hypertension (SHR: 1.28, 95% CI: 1.13--1.44) at baseline. In contrast, high s-cholesterol (SHR: 1.06, 95% CI: 0.87--1.30) was not significantly related to stroke and being a smoker at baseline (SHR: 0.86, 95% CI: 0.77--0.95) was paradoxically associated with a lower risk. Table 2A 35-year follow-up with subdistribution hazard ratio (95% CI) adjusted for age for coronary heart disease and stroke with regard to individual risk factors at baselineRisk factorsNumber at riskEvents^a^Total observation yearsIRR^b^ (95% CI)Adjusted SHR^b^ (95% CI)CHD (mmol/L) S-cholesterol  \<5.070318018 0001 (ref)1 (ref)  5.0--5.9198654351 090.51.08 (0.91--1.27)1.10 (0.93--1.30)  6.0--6.9236481857 901.91.45 (1.24--1.71)1.50 (1.28--1.76)  ≥7.0212187648 7991.86 (1.58--2.19)1.93 (1.65--2.26) SBP (mmHg)  \<140255269266 570.91 (ref)1 (ref)  140--159257387863 3771.31 (1.18--1.45)1.31 (1.19--1.45)  ≥160204984745 843.51.72 (1.55--1.90)1.68 (1.52--1.86) Smoking  Non-smoker3577111295 528.81 (ref)1 (ref)  Smoking3597130580 262.61.38 (1.27--1.49)1.26 (1.16--1.36)Hypertension  Non-hypertensive217156857 501.21 (ref)1 (ref)  Hypertensive5003184911 82901.54 (1.40--1.69)1.51 (1.38--1.66)  Antihypertensive medication3671667794.71.56 (1.33--1.83)1.55 (1.31--1.82)Stroke (mmol/L) S-cholesterol  \<5.070312818 031.41 (ref)1 (ref)  5.0--5.9198635352 106.90.97 (0.79--1.18)0.99 (0.81--1.21)  6.0--6.9236445760 870.41.09 (0.89--1.32)1.09 (0.90--1.33)  ≥7.0212139752 590.51.10 (0.90--1.35)1.06 (0.87--1.30) SBP (mmHg)  \<140255241868 831.81 (ref)1 (ref)  140--159257346866 617.51.13 (0.99--1.29)1.11 (0.97--1.26)  ≥160204944948 149.91.48 (1.29--1.69)1.37 (1.20--1.57) Smoking  Non-smoker357771598 698.11 (ref)1 (ref)  Smoking359762084 901.10.99 (0.89--1.11)0.86 (0.77--0.95) Hypertension  Non-hypertensive217134159 374.11 (ref)1 (ref)  Hypertensive500399412 42251.35 (1.19--1.53)1.28 (1.13--1.44)  Antihypertensive medication367858131.41.43 (1.15--1.79)1.31 (1.05--1.65)[^3][^4]

Effect of risk groups {#s3b}
---------------------

To estimate the cumulative effect of developing a first CHD or stroke event, all participants were stratified into one of five risk groups (optimal levels, low risk, moderate risk, elevated risk, and high risk) based on their burden of risk factors at baseline in 1970--73. *Table [3](#EHS458TB3){ref-type="table"}* shows the long-term SHR with 95% CI and the cumulative effect on CHD and stroke separately after 35 years when adjusted for age and competing risk. In general, each additional risk factor at baseline increased the risk of developing a CHD or stroke. Individuals with several risk factors at baseline (s-cholesterol ≥6.0 mmol/L, SBP ≥160 mmHg or antihypertensive treatment and being a current smokers at baseline) had a SHR of 2.89 (95% CI: 2.41--3.47) for CHD but 1.21 (95% CI: 0.96--1.53) for stroke compared with low-risk individuals (*Table [3](#EHS458TB3){ref-type="table"}*). Table 3A 35-year follow-up with subdistribution hazard ratio (95% CI) adjusted for age for coronary heart disease and stroke with regard to risk groupsRisk groupsNumber at riskEvents^a^Total observation yearsIRR^b^ (95% CI)Adjusted SHR^b^ (95% CI)CHD Risk groups^b^  Optimal risk130203855.60.77 (0.49--1.23)0.69 (0.44--1.07)  Low risk84218424 047.71 (ref)1 (ref)  Moderate risk286787774 1501.54 (1.31--1.80)1.48 (1.27--1.73)  Elevated risk2645100160 530.82.16 (1.84--2.52)2.01 (1.73--2.35)  High risk69033513 207.33.22 (2.69--3.86)2.89 (2.41--3.47)Stroke Risk groups^b^  Optimal risk130243760.21.12 (0.72--1.72)1.10 (0.72--1.70)  Low risk84214424 429.21 (ref)1 (ref)  Moderate risk286753576 677.21.18 (0.98--1.42)1.10 (0.92--1.32)  Elevated risk264549464 1961.30 (1.08--1.56)1.12 (0.93--1.35)  High risk69013814 536.61.56 (1.24--1.97)1.21 (0.96--1.53)[^5][^6]

In the final analysis, we estimated the short-term and long-term cumulative effect after adjusting for age and competing risk. For the first 10 years, individuals with adverse levels of risk factors at baseline (high risk) had an 18.1% risk of CHD compared with 1.3% for those with low risk (reference group). Corresponding results for stroke during the first 10 years were 3.2% compared with 0.5% (*Figure [1](#EHS458F1){ref-type="fig"}*). In the second part, the follow-up time was extended to 35 years in order to estimate the long-term effect of multiple risk factors. For CHD those with the most adverse levels of risk factors at baseline had a 47.8% risk compared with 19.6% for stroke after 35 years (*Figure [1](#EHS458F1){ref-type="fig"}*). Figure 1Cumulative incidence curves adjusted for competing risk of death by different risk groups for coronary heart disease and stroke, respectively. The 10-year cumulative risk for (*A*) coronary heart disease, (*B*) stroke and the 35-year cumulative risk for (*C*) coronary heart disease, and (*D*) stroke.

Discussion {#s4}
==========

Principal findings {#s4a}
------------------

In the present study, we aimed to determine to what extent the use of age, s-cholesterol, SBP, and smoking status at baseline can be used to predict the short-term and long-term risk of both CHD and stroke separately among 7174 middle-aged men over an extended follow-up. For the first 10 years, we observed that these risk factors could effectively predict the cumulative risk of CHD but not stroke to the same extent. This did not change over time when the follow-up time was extended until old age. As a result, high-risk individuals had a markedly high-cumulative risk for CHD but not in a similar manner for stroke after 35 years.

Effect on individual risk factors {#s4b}
---------------------------------

We found that the five major risk factors were all related to CHD and stroke after 35 years with the exception of s-cholesterol. However, the impact of each factor differed according to both the endpoint under study and the outcome. Consistent with previous reports, hypertension, antihypertensive medication, and high SBP at baseline were related to both CHD and stroke.^[@EHS458C13]--[@EHS458C17]^ High s-cholesterol levels were strongly associated with CHD but not stroke. Findings from previous epidemiological studies in this subject are inconsistent. For example, some have reported an inverse association of s-cholesterol and haemorrhagic stroke while other suggests that the ratio of HDL cholesterol and LDL cholesterol levels may be a better predictor.^[@EHS458C17]--[@EHS458C19]^ However, most epidemiological studies have failed to find a direct association between total cholesterol and overall stroke risk.^[@EHS458C20]--[@EHS458C22]^For the smoking status, we found that being a current smokers at baseline were associated with an increased risk of CHD but not for stroke after adjusting for competing risk. However, this result should not be interpreted to mean that smoking has no effect on stroke. On the contrary, previous epidemiological evidences have showed a strong association between smoking and having an increased risk of stroke.^[@EHS458C17],[@EHS458C23],[@EHS458C24]^ In an earlier 28-year follow-up period of this study population by Harmsen *et al.*^[@EHS458C25]^ smoking was found to be a risk factor for stroke during the first 21 years, but for the final period of 7 years no significant association was found. This effect could possibly be attributed to a decreasing proportion of smokers over time. For example, in Gothenburg smoking decreased from 50% in 1970--73 to \<30% in 1995.^[@EHS458C26]^ Accordingly a diminishing number of smokers might have contributed to an underestimation of the true risk of smoking.^[@EHS458C25],[@EHS458C27]^

The effect of cumulative risk factors {#s4c}
-------------------------------------

In a long-term perspective, the SHR among high-risk individuals, compared with those with low risk, was approximately twice as high for CHD compared with stroke after 35 years when adjusted for age and competing risk (*Table [3](#EHS458TB3){ref-type="table"}*). In the next step, we focused on the short-term and long-term effect on CHD and stroke.

For the first 10 years, we observed that the predictability of CHD and stroke based on the risk factors age, s-cholesterol, SBP, and smoking status differed considerably, with the cumulative risk among high-risk individuals being substantially higher for CHD than stroke. The difference between the two conditions is chiefly due to the small number of stroke events, since stroke is uncommon among younger and middle-aged people (in this study only numbering 118 stroke events for the first 10 years).^[@EHS458C6]^

After 35 years, when the follow-up time was extended until old age individuals with adverse levels of risk factors at baseline had a markedly high risk of CHD but not for stroke to the same extent. For the individual risk factors, only high SBP had a major impact on stroke. Therefore, our findings suggest that the effect of the sum of the individual risk factors differs for CHD and stroke. In addition, early deaths from CHD occur mainly among high risk individuals and as a result, the number of men with high risk decreases at higher rate over time which in a longer follow-up could have an effect on the risk estimates for stroke. To further improve the risk assessment, it is our belief that stroke should be separated from the general concept of CVD when developing risk models for use in middle-aged populations. Adding other major risk factors such as diabetes, obesity, or lack of exercise may be a more effective way to predict the short-term and long-term risk of stroke than focusing on any single-risk factor.

There are limitations to our study. First, risk factors in our study were generally high. This applies particularly to BP levels. However, different methodologies have been used, for instance using the lowest BP reading in a series or measuring in the morning as opposed to in the late afternoon (4:30--7:00 p.m.).^[@EHS458C28]--[@EHS458C30]^ In a separate analysis, a subsample of the men was selected and screened during the morning in a more relaxed environment, resulting in lower mean BP levels, where a cut-off point of 175/115 mmHg measured in the afternoon would correspond to a morning level of 162/101 mmHg.^[@EHS458C31]^ Moreover, BP levels have been shown to be generally lower in North America compared with European populations.^[@EHS458C32]^ Additionally, BP levels in Northern Europe have declined, with Gothenburg levels not dramatically different to other communities at the time.^[@EHS458C33],[@EHS458C34]^ Secondly, s-cholesterol levels were also high; however, the mean value was lower in the present study than in other populations at the time such as the Oslo study and the FINRISK study (North Karelia and Savoy county area in 1972).^[@EHS458C33],[@EHS458C35],[@EHS458C36]^ As a result, the risk factors in the present study are comparable with other communities at the time. In addition, smoking rates were quite high and accordingly the optimal group was very small (1.8% of the total population). To provide meaningful comparisons, the low-risk group was therefore used as the reference group when calculating the SHR. Thirdly, we used only single measurements for the risk factors and these may have changed during the 35-year follow-up time. Even so, and with these limitations in mind, one-single measurement of these main risk factors in midlife was quite predictive for events occurring decades after the baseline investigation.

Conclusions {#s5}
===========

In conclusion, the prediction of CHD and of stroke in middle-aged men differs substantially when using the conventional risk factors SBP, s-cholesterol, and smoking. Our results indicate that the cumulative risk based on these traditional risk factors can effectively be used to predict both the short-term and long-term risk of CHD but not stroke to the same extent.
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[^1]: ^a^SD, standard deviation.

[^2]: ^b^Optimal risk: SBP ≤140 mmHg without antihypertensive treatment, s-cholesterol \<5.0 mmol and non-smoker; low risk: SBP = 140--159.9 mmHg without antihypertensive treatment, s- cholesterol 5.0--5.59 mmol, and non-smoker; moderate risk: SBP ≥160 mmHg or antihypertensive treatment or s-cholesterol ≥6.0 mmol/L or current smoker; elevated risk: SBP ≥160 mmHg or antihypertensive treatment and/or s-cholesterol ≥6.0 mmol/L, and/or current smoker; high risk: SBP ≥160 or antihypertensive treatment and s-cholesterol ≥6.0 mmol/L, and current smoker or diabetic.

[^3]: ^a^First ever occurrence of a CHD or stroke.

[^4]: ^b^Age-adjusted incidence ratio (IRR) and subdistribution hazard ratio (SHR).

[^5]: ^a^First ever occurrence of a CHD or stroke.

[^6]: ^b^Age-adjusted incidence ratio (IRR) and subdistribution hazard ratio (SHR).
